Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Multiple effects of α1-antitrypsin on breast carcinoma MDA-MB 468 cell growth and invasiveness

Zelvyte, I; Lindgren, S; Janciauskiene, S

European Journal of Cancer Prevention: April 2003 - Volume 12 - Issue 2 - p 117-124
Research Papers

The degradation of extracellular matrix during cancer invasion results from the action of several protease and protease inhibitor systems. α1-Antitrypsin (AAT) is a serine proteinase inhibitor produced by various tumour cells, and its plasma concentration rises during inflammation, infection and malignant diseases. AAT is found in a native, inhibitory active form, but also in other, non-inhibitory forms including cleaved and/or degraded. To test a hypothesis that AAT dependent on its molecular form may have multiple effects on tumour cell behaviour, breast cancer cells, MDA-MB 468, were cultured alone or stimulated with a native AAT or its C-terminal fragment (C-36) at a concentration of 5 μmol/l for 2, 24 and 48 hours. Native AAT added to the cells for 2 hours enhanced transforming growth factor beta 1 (TGFβ1) levels by 50%, but inhibited cell proliferation (by 61%), reduced interleukin 6 (IL-6) levels (by 87%) and activity (by about 66%), compared with non-stimulated cells. Native AAT showed similar, but less pronounced, effects when added to the cells for 24 and 48 hours. Under the same experimental conditions the cells exposed to the C-36 peptide significantly increased in proliferation, invasiveness and showed higher IL-6 levels. In addition, cells treated with the C-36 for 48 hours increased in NFκB (nuclear factor kappa B) activity. These results indicate that AAT, dependent on its molecular form, can both suppress and induce breast tumour cell biological activity in vitro.

Department of Medicine, University Hospital Malmö, Wallenberg Laboratory, Ing.46, Plan 2, UMAS, S-20502, Malmö, Sweden

Correspondence to: S Janciauskiene.

Fax: (+46) 4033 7041. E-mail:

Received 16 July 2002 Accepted 29 November 2002

© 2003 Lippincott Williams & Wilkins, Inc.